To The Moon

Will BioNTech 🚀🚀🚀 again with the Concerning Covid-Omicron Outbreak 💉🦠 $BioNTech SE(BNTX)$

BACKGROUND:

(1) On 26 November 2021, WHO designated the variant B.1.1.529 (named Omicron) a variant of concern as it has an abundance of mutations-including 26 that are unique to the variant & more than 30 on the spike protein, which is the viral protein that vaccines train the immune system to recognize & attack.

(2) The Omicron variant spreads more easily than the original SARS-CoV-2 virus & the Delta variant. In the first months of 2022, an Omicron sub-variant called BA.2 began to spread even faster than other Omicron variants. BA.4 & BA.5 are thought to be even more transmissible. Experts are saying that the Omicron BA.4 & BA.5 sub-variants seem to have the ability to elude some of the antibodies produced after vaccinations and infections, including those caused by some Omicron sub-variants. 

(3) In late June, a committee of experts recommended the FDA update booster shots to target BA.5 and BA.4 subvariants of Omicron, with a plan to make such boosters available later in the year.

QN: How will the above background information help me in my investing?

ANS: The background information implies that the existing vaccines that people have been injected are not as effective & new booster shots would be required ➡️ This in turn means that companies with the Omicron vaccine booster will benefit from increased sales ➡️ Which means investors will have renewed interest in vaccine stocks & be willing to pay more to obtain the shares ➡️ Therefore, pushing up the stock price.

COMPANY PROFILE: With decades of deep immunology expertise and experience in developing & optimizing mRNA as part of its broad suite of novel technologies, BioNTech is working with the global community to defeat life-threatening and serious diseases such as cancer, COVID-19, malaria and tuberculosis. The first ever approved mRNA vaccine was created in the labs of BioNTech in Mainz, Germany.

CUTTING EDGE PRODUCTS:

(1) mRNA Therapeutics

(2) Engineered Cell Therapies

(3) Antibodies

(4) Small Molecule Immunomodulators

For more details, refer to: https://www.biontech.com/int/en/home.html

INVESTOR CONSIDERATIONS:

(1) Dividend Yield: 0% (Note:BNTX only listed on Nasdaq in 2019)

(2) 52W Low/High: 117.08/464.00

(3) P/E (TTM): 2.942, EPS (TTM): 54.87

(4) Market Cap: 39.23B (before

(5) Debt ratio: Relatively low at 24.87% for FY21

(6) After reaching the peak price of USD 464 in August 2021, it has bottom twice at about USD 110-120+ in March & June 2022, & mostly peaks at about USD 150-170+ ➡️ Investors seem to have lost interest & a >USD 300 peak seems less likely?

(7) Pfizer & BioNTech have announced a new vaccine supply agreement with the US government to deliver 105 million doses (*may include adult Omicron-adapted vaccines if approved by FDA) at 3.2 billion dollars with an option to buy an additional 195 million doses.

Source websites: WHO, Yale Medicine, Pfizer, BioNTech.

What are your thoughts my 🐯🐯🐯 friends?

(1) For a relatively stable stock with dividend yield as a side income, & a proven track record to be able to withstand a recession, I will choose Pfizer $Pfizer(PFE)$However, if one is looking for faster capital gains (*with more risks as well of course), then BioNTech will be a good choice?

(2) A safe price to buy BioNTech will be at USD 125 & a good price to sell at will be USD 165? 

As usual-🤔💭 Consider POV & Actions of investors + 👩🏻‍💻👨🏻‍💻 Research + 🗑FOMO & Greed = Investing Wisely 🤓🤗 + Accumulating Wealth 💵💰

Related posts from me 🕵🏻👩🏻‍💻:

-Pfizer 🧪🧫🔬💊💉🦠 is a BUY & Safe for Holding-Recession or Not

-Is Novavax 💉🦠 still a Vaccine Competitor & Safe for Holding if There’s a Recession? 

@TigerStars@Daily_Discussion